Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43926710" target="_blank" >RIV/00064173:_____/24:43926710 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43926710 RIV/00216208:11130/24:10477952 RIV/00064203:_____/24:10477952

Výsledek na webu

<a href="https://doi.org/10.1111/jdv.19916" target="_blank" >https://doi.org/10.1111/jdv.19916</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.19916" target="_blank" >10.1111/jdv.19916</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

Popis výsledku v původním jazyce

Our objective was to investigate the potential link between TNF-alpha inhibitors and the development of cSCC in HS lesions.We prospectively collected data of 299 patients from 18 hospitals in the Czech Republic between January 2011 and March 2023 with moderate to severe HS, treated with adalimumab. Data collection was carried out through the nationwide BIOREP registry, a database that includes patients treated with biologic agents for skin conditions. All patients provided written informed consent. The study included HS patients of any age who received at least one dose of adalimumab (40 mg weekly). Minimal and maximal time of follow-up ranged between 6 and 159 months.

Název v anglickém jazyce

Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

Popis výsledku anglicky

Our objective was to investigate the potential link between TNF-alpha inhibitors and the development of cSCC in HS lesions.We prospectively collected data of 299 patients from 18 hospitals in the Czech Republic between January 2011 and March 2023 with moderate to severe HS, treated with adalimumab. Data collection was carried out through the nationwide BIOREP registry, a database that includes patients treated with biologic agents for skin conditions. All patients provided written informed consent. The study included HS patients of any age who received at least one dose of adalimumab (40 mg weekly). Minimal and maximal time of follow-up ranged between 6 and 159 months.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

1468-3083

Svazek periodika

38

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

"e807"-"e809"

Kód UT WoS článku

001177663300001

EID výsledku v databázi Scopus

2-s2.0-85186574119